Liao Jiabao, Xie Xuehua, Gao Jinmei, Zhang Zhaiyi, Qu Fei, Cui Huantian, Cao Yongjun, Han Xue, Zhao Jie, Wen Weibo, Wang Hongwu
Jiaxing Hospital of Traditional Chinese Medicine, Zhejiang Chinese Medical University, Jiaxing, Zhejiang, China.
Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu, China.
Evid Based Complement Alternat Med. 2021 Mar 20;2021:5522755. doi: 10.1155/2021/5522755. eCollection 2021.
Jian-Gan-Xiao-Zhi decoction (JGXZ), composed of , , , and other 9 types of herbs, has demonstrated beneficial effects on nonalcoholic fatty liver disease (NAFLD). However, the mechanisms behind JGXZ's impact on NAFLD remain unknown.
In this study, a NAFLD rat model induced by a high-fat diet (HFD) received oral treatment of JGXZ (8 or 16 g crude herb/kg) for 12 weeks. The therapeutic effects of JGXZ on NAFLD model rats were investigated through blood lipid levels and pathological liver changes. 16S rRNA analysis was used to study the changes in gut microbiota after JGXZ treatment. The expressions of occludin and tight junction protein 1 (ZO-1) in the colon were investigated using immunostaining to study the effects of JGXZ on gut permeability. The anti-inflammatory effects of JGXZ were also studied through measuring the levels of IL-1, IL-6, and TNF- in the serum and liver.
JGXZ treatment could decrease body weight and ameliorate dyslipidemia in NAFLD model rats. H&E and Oil Red O staining indicated that JGXZ reduced steatosis and infiltration of inflammatory cells in the liver. 16S rRNA analysis showed that JGXZ impacted the diversity of gut microbiota, decreasing the -to- ratio, and increasing the relative abundance of probiotics, such as , , and . Gut permeability evaluation found that the expressions of ZO-1 and occludin in the colon were increased after JGXZ treatment. Moreover, JGXZ treatment could decrease the levels of IL-1, IL-6, and TNF- in the serum and liver.
Our study illustrated that JGXZ could ameliorate NAFLD through modulating gut microbiota, decreasing gut permeability, and alleviating inflammatory response.
健肝消脂汤(JGXZ)由[具体药材1]、[具体药材2]、[具体药材3]和其他9种草药组成,已证明对非酒精性脂肪性肝病(NAFLD)具有有益作用。然而,JGXZ对NAFLD影响的机制尚不清楚。
在本研究中,高脂饮食(HFD)诱导的NAFLD大鼠模型接受JGXZ(8或16 g生药/kg)口服治疗12周。通过血脂水平和肝脏病理变化研究JGXZ对NAFLD模型大鼠的治疗效果。采用16S rRNA分析研究JGXZ治疗后肠道微生物群的变化。通过免疫染色研究结肠中闭合蛋白和紧密连接蛋白1(ZO-1)的表达,以研究JGXZ对肠道通透性的影响。还通过测量血清和肝脏中IL-1、IL-6和TNF-[具体指标]的水平来研究JGXZ的抗炎作用。
JGXZ治疗可降低NAFLD模型大鼠的体重并改善血脂异常。苏木精-伊红(H&E)和油红O染色表明,JGXZ减少了肝脏中的脂肪变性和炎性细胞浸润。16S rRNA分析表明,JGXZ影响肠道微生物群的多样性,降低[具体指标1]与[具体指标2]的比例,并增加益生菌(如[益生菌1]、[益生菌2]和[益生菌3])的相对丰度。肠道通透性评估发现,JGXZ治疗后结肠中ZO-1和闭合蛋白的表达增加。此外,JGXZ治疗可降低血清和肝脏中IL-1、IL-6和TNF-[具体指标]的水平。
我们的研究表明,JGXZ可通过调节肠道微生物群、降低肠道通透性和减轻炎症反应来改善NAFLD。